therapy with cetuximab. Both patients developed severe thoracic and cervicothoracic pain following treatment. In both cases, extensive paraspinal abscess formation proved to be the underlying cause. One patient was treated conservatively; the other one had to undergo surgical intervention. Conclusions: Awareness of multifaceted therapy-related complications is mandatory when patients receive multimodal treatment including targeted therapies. Unexplained pain syndromes in this context should raise suspicions concerning possible infectious complications and should lead to early use of magnetic resonance imaging.
Summary

Background:
Patients with squamous-cell carcinoma of the head and neck (SCCHN) on palliative therapy usually have a bad prognosis and suffer from various symptoms. With increasing use of targeted agents in cancer patients at the end of life, the correct assignment of therapy-related symptoms becomes increasingly difficult as cancer-related symptoms usually increase as well. Case Report : We report on 2 cases of patients with SCCHN who received multimodal treatment including palliative
Introduction
Over the last 2 decades, targeted therapies have dramatically changed the treatment of cancer. They are now routinely used in many malignancies, frequently achieving significant rates of response and improved survival. However, adverse effects remain an important issue [1] . Many organ systems may be affected, resulting in a plenitude of symptoms of varying severity. With increasing use of targeted agents in cancer patients at the end of life [2] , the correct assignment and interpretation of therapy-related symptoms becomes increasingly difficult as cancer-related symptoms usually increase as well. Moreover, back pain in elderly patients is commonly misjudged as non-specific. Here, we report on 2 patients with incurable squamous-cell carcinoma of the head and neck (SCCHN) and severe pain due to paraspinal abscess formation following treatment with cetuximab.
Case Report 1
A 62-year-old patient was diagnosed with a hypopharynx carcinoma in December 2014 and initially treated with definitive radiochemotherapy. Upon local recurrence 6 months later, she received palliative chemotherapy with docetaxel weekly combined with cetuximab. As computed tomography (CT) scans showed stable disease after 4 cycles, the therapy was deescalated in January 2016 to cetuximab every second week (500 mg/m 2 ) alone, which the patient received till April 2016.
With local recurrence, swallowing had triggered pain in the throat, which was well controlled with the use of transmucosal fentanyl pro re nata (p.r.n.; as needed). In December 2015, the patient started to complain about increasing pain in the neck and the right cervical region. Transdermal fentanyl was started and subsequently escalated up to 50 μg/h in the next months, without satisfactory pain control. Addition of dipyrone and pregabaline did not give any pain relief either. A CT scan performed in March 2016 showed no change of the formerly known tumor in the left hypopharynx, without explanation for the increasingly severe pain. The patient was referred to the palliative care unit (PCU) 1 month later, with constant pain irradiating from the back of the neck and the right cervical region to the shoulder and with frequent ripping pain attacks triggered by swallowing. A magnetic resonance imaging (MRI) scan performed the day after admission revealed retropharyngeal/prevertebral abscesses and concomitant osteitis in C4-7. The patient received parenteral antibiotics for 1 week followed by an oral regime for a total of 4 weeks. The pain decreased rapidly the day after the antibiotics were initiated. C-reactive protein (CRP) decreased from 81 to 26 mg/l within 1 week. Subsequent MRI and CT scans revealed complete resolution of the abscesses ( fig. 1) . A subsequent clinically inapparent spondylodiscitis C5/6 was treated with oral antibiotics for another 3 months from September till December 2016, when repeated imaging confirmed resolution of the inflammatory process together with ongoing stable tumor disease. No further tumor-specific therapy was applied. In December 2017, the patient remains free of pain with stable disease.
Case Report 2
A 67-year-old man was diagnosed with oropharynx carcinoma in 2011. Due to several recurrences, he repeatedly underwent extensive surgery and a total of 6 courses of adjuvant chemotherapy with cisplatin, 5-fluorouracil (5-FU), and cetuximab in 2011 and 2013. Due to further local progression with no option for further surgery, he received another 4 courses of palliative cetuximab-containing chemotherapy (cisplatin, 5-FU, cetuximab 250 mg/m 2 on days 1, 8, 15) from September 2015. Cetuximab was omitted during the last course, and chemotherapy was stopped at the end of November 2015, because his general condition worsened and the therapy was rather poorly tolerated. A whole-body CT scan in December showed a slight decrease in size of the local palatine tumor recurrence and degenerative skeletal changes without distant metastasis. In November 2015, the patient had started to complain about lower-back pain, which initially was well controlled with tramadolol 200 mg/day and dipyrone 4 g/day. In January 2016, the patient presented to the emergency department with severe thoracic pain. Acute myocardial infarction and pulmonary embolism were ruled out. A thoracic CT scan showed bilateral pneumonia; blood cultures revealed infection with Staphylococcus aureus. Antibiotic therapy was initiated and the port catheter system was explanted. Analgetics were switched to oral morphine 80 mg/day; however, moderate thoracic pain remained a problem. During February 2016, the dose of morphine was further escalated to 120 mg/ day. In view of the findings of the January CT scan, the pain (now located in the cervical region as well) was thought to be due to degenerative changes of the spine. At the beginning of March 2016, the patient was admitted to the PCU with excruciating thoracic pain, needing 180 mg of parenteral morphine during the first 24 h. CT and MRI scans now revealed thoracic, lumbar, and suspected cervical spondylodiscitis with concomitant thoracic and lumbar paravertebral abscesses and bone destruction. In retrospect, a small abscess was already present in CT imaging in January ( fig. 2 ). Surgical abscess removal and vertebral stabilization were performed. Staphylococcal infection was detected in the resected tissue samples. In the further follow-up, morphine could be tapered down to 60 mg/day with sustained good pain control. Due to the progressive local tumor, off-label therapy with nivolumab was initiated in October 2016, resulting in stable disease until March 2017, when further disease progress was detected.
Discussion
In both case reports, emergence of severe pain due to paraspinal abscess formation occurred in temporal relationship with palliative treatment of SCCHN with cetuximab.
Cetuximab is a chimeric monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR). It compromises the tumor cell in many ways; e.g., it decreases cell proliferation and induces antibody-dependent cell-mediated cytotoxicity (ADCC). Cetuximab may also inhibit DNA repair mechanisms [3, 4] .
In general, cetuximab is considered a well-tolerated agent. Cutaneous and mucosal reactions are dominant side effects, which can usually be managed easily [5] . However, 45-100% of patients acquire an acneiform rash, and only a minority develops dermatitis or higher-grade skin toxicities, but little is known about the impact this may have on the individual [6] . The onset is typically a few days after therapy, with a peak about 2 weeks after. The mechanisms are poorly understood, but inflammatory tissue reactions, increased apoptosis, and a diminished stem cell pool in non-malignant keratinocytes and epidermal cells are the results [7] , which is reminiscent of the bone marrow damage caused by cytotoxic chemotherapy. The consequences of severe inflammatory skin toxicity were already observed early, with multiple and ongoing therapies like irradiation as additional risk factor [8, 9] . Although the febrile neutropenia rates were similar in a randomized clinical trial adding cetuximab to platinum-based chemotherapy, the rates of sepsis were higher with cetuximab compared to chemotherapy alone (4% vs. < 1%; p = 0.02) [10] .
Multiple cutaneous and subcutaneous abscess formation has been reported in 2 case reports [11, 12] . Then, patients with SCCHN were under combined radiotherapy and cetuximab, and the onset of abscess-forming complications was late at 7 and 9 weeks, respectively. Further, bacterial superinfections of skin and appendages were reported with typical onset months after initiation of cetuximab, i.e. after a mean of 28.6 weeks with a range of 3-144 weeks [13] .
In light of these findings, a causal relationship between the severe infectious complications of our case reports and the palliative treatment with cetuximab has to be taken into account. Both patients received cetuximab for SCCHN and both developed paraspinal abscesses and spondylodiscitis in the upper spine after a trajectory common to current treatment standards in SCCHN. Thus, prior extensive surgery or irradiation might be an additional risk factor.
A differential diagnosis is osteoradionecrosis (ORN), a slowhealing radiation-induced ischemic necrosis of the bone with associated soft-tissue necrosis of variable extent, which occurs in up to 57% of patients after irradiation of head and neck cancer [14, 15] . Since osteomyelitis and osteodiscitis are proposed to represent infectious complications of underlying ORN [16] , patient 1 possibly initially suffered from this.
Our case reports imply clinical and research consequences. Clinical awareness of multifaceted therapy-related complications is mandatory when patients receive multimodal treatment including targeted therapies. Unexplained pain syndromes in this context should raise suspicions of possible infectious complications and should lead to early use of MRI, as its sensitivity in early stages is superior to that of CT [17, 18] . Further, our case reports underline the general importance of continuous proper and careful assessment of pain in cancer patients, rather than a purely symptomatic long-term analgesic treatment. Research on the appropriate length of treatment with targeted therapies in the palliative context is highly desirable in the light of possibly life-threatening side effects. Immunogenic effects of anti-EGFR mAbs interfering with ADCC in bacterial defense could be considered beyond the well-known antiproliferative effects of EGFR inhibitors on non-mutated tissue. Moreover, the patient's burden as well as the economic burden even of non-life-threatening side effects may be considerable [6, 19] .
